Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Weeks After Bydureon Launch, Amylin Looks Like A Takeout Target

This article was originally published in The Pink Sheet Daily

Executive Summary

The diabetes drug maker has reportedly spurned a buyout offer at a 43% premium, driving up its share price – and perhaps discouraging it from pursuing the partnership it seeks.

Advertisement

Related Content

Intarcia Forgoes Partnerships, Raises $210M In Equity And Debt Instead
Bristol And AstraZeneca Make A Splash In Diabetes With Joint Purchase Of Amylin
Deals Of The Week: Express Scripts/Walgreens, Par/TPG, Amicus/GSK
With Bristol/AstraZeneca In Driver’s Seat, GLP-1 Race Takes A Turn
AstraZeneca, BMY To Target Disease Management And Primary Care Synergies With Amylin Acquisition
$7 Billion Amylin Buyout Boosts BMS, AZ Diabetes Partnership
Business News, In Brief
With Bydureon’s U.S. Approval, Amylin Extends Exenatide Franchise
With Lilly Out, Amylin’s Future Is Tied To Bydureon
Amylin, Lilly End Exenatide Tie-Up, Marking End To Litigation

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS073946

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel